Table 2.

Disease-specific survival (DSS) rates based on immune cell score (ICS) in primary small bowel neuroendocrine tumors and lymph node metastases.

DSS	No. of Patients	ICS Low (0–1)	ICS High (2–4)	p
Primary tumors	113	5-year: 92.6%	5-year: 87.8%
		10-year: 53.8%	10-year: 79.4%	0.507
Lymph node metastases	75	5-year: 88.9%	5-year: 90.4%
		10-year: 71.1%	10-year: 59.8%	0.466